Roth MKM Downgrades Acer Therapeutics to Neutral, Announces $1.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has downgraded Acer Therapeutics from Buy to Neutral and set a price target of $1.5.
September 01, 2023 | 8:37 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acer Therapeutics has been downgraded from Buy to Neutral by Roth MKM, with a new price target of $1.5.
The downgrade from Buy to Neutral by Roth MKM indicates a less optimistic outlook for Acer Therapeutics. This could potentially lead to a decrease in the stock's price in the short term. The new price target of $1.5 also suggests a lower valuation for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100